243 related articles for article (PubMed ID: 26632406)
1. Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer.
Choi YJ; Kim MJ; Lee BH; Kwon MJ; Hwang HS
Yonsei Med J; 2016 Jan; 57(1):232-7. PubMed ID: 26632406
[TBL] [Abstract][Full Text] [Related]
2. Incidental focal colorectal ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography.
Cho SH; Kim SW; Kim WC; Park JM; Yoo IeR; Kim SH; Oh ST
World J Gastroenterol; 2013 Jun; 19(22):3453-8. PubMed ID: 23801838
[TBL] [Abstract][Full Text] [Related]
3. The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer.
Shi D; Cai G; Peng J; Li D; Li X; Xu Y; Cai S
BMC Cancer; 2015 Dec; 15():991. PubMed ID: 26689966
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
5. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
6. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
9. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Metabolic Parameters Derived From
Liu H; Ye Z; Yang T; Xie H; Duan T; Li M; Wu M; Song B
Front Immunol; 2021; 12():724464. PubMed ID: 34512653
[TBL] [Abstract][Full Text] [Related]
11. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
12. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.
Kocael A; Vatankulu B; Şimşek O; Cengiz M; Kemik A; Kocael P; Halaç M; Sönmezoğlu K; Ulualp K
Tumour Biol; 2016 Mar; 37(3):3871-7. PubMed ID: 26476536
[TBL] [Abstract][Full Text] [Related]
14. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of ¹⁸F-FDG PET-CT maximum standard uptake value and T/N ratio with the prognosis of postoperative colorectal cancer].
Wang X; Peng G; Zhang X; Chen Z; Zhang B; Li Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):232-7. PubMed ID: 25809325
[TBL] [Abstract][Full Text] [Related]
16. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
18. Predictive Role of Functional Visceral Fat Activity Assessed by Preoperative F-18 FDG PET/CT for Regional Lymph Node or Distant Metastasis in Patients with Colorectal Cancer.
Pahk K; Rhee S; Kim S; Choe JG
PLoS One; 2016; 11(2):e0148776. PubMed ID: 26862754
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
20. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
